Brian Lehman, MBA, MHA, RPh: Impact of Biosimilar Insulin on Patient Affordability

Brian Lehman, MBA, MHA, RPh, director, Medical Account Management and Strategic Alliances, Sandoz, discusses the March 2020 transition of insulin to the biologics pathway.
January 31, 2020


The Biologic Price Competition and Innovation Act actually has a portion of the act in March 23, 2020. The insulin products and similar protein products will become biologic products. So they move from the Food, Drug and Cosmetic Act over to the Public Health Service Act, and they'll go from [New Drug Application] NDAs to [Biologic License Application] BLAs. With that situation, what it's going to allow is biosimilar products to then compete against the 351(a) insulin products, and this competition that's going to occur will help improve affordability and access of insulin products for patients.


Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.